Showing results (1281-1290 of 3,716) with videos related to
Sort By:
Pageof 372
Investigational New Drugs|March 12, 2014
Differences in maximum tolerated doses and approval doses of molecularly targeted oncology drug between Japan and Western countriesHideki Maeda, Tatsuo KurokawaInvestigational New Drugs|March 13, 2014
Randomized phase II trial of sorafenib alone or in combination with carboplatin/paclitaxel in women with recurrent platinum sensitive epithelial ovarian, peritoneal, or fallopian tube cancerAnita Schwandt, Vivian E von Gruenigen, Robert M Wenham, et al.Investigational New Drugs|April 1, 2014
Successful readministration of trastuzumab after severe immune reactions in two breast cancer patientsR Tanz, N Meillan, N Libert, et al.Investigational New Drugs|March 5, 2021
Identify potential miRNA-mRNA regulatory networks contributing to high-risk neuroblastomaFeng-Ling Shao, Qing-Qing Liu, Shan WangInvestigational New Drugs|March 8, 2021
Rapamycin synergizes the cytotoxic effects of MEK inhibitor binimetinib and overcomes acquired resistance to therapy in melanoma cell lines in vitroOxana O Ryabaya, Ivan S Abramov, Dmitry A Khochenkov, et al.Investigational New Drugs|March 8, 2021
A phase Ib, open label, dose escalation trial of the anti-CD37 monoclonal antibody, BI 836826, in combination with ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemiaAlexey V Danilov, Stephen E Spurgeon, Tanya Siddiqi, et al.Investigational New Drugs|March 12, 2021
Discovery of MTR-106 as a highly potent G-quadruplex stabilizer for treating BRCA-deficient cancersMeng-Zhu Li, Tao Meng, Shan-Shan Song, et al.Investigational New Drugs|March 11, 2021
Efficacy and safety of lurbinectedin and doxorubicin in relapsed small cell lung cancer. Results from an expansion cohort of a phase I studyMaría Eugenia Olmedo, Martin Forster, Victor Moreno, et al.Investigational New Drugs|March 18, 2017
Lung cancer and β-glucans: review of potential therapeutic applicationsRaheleh Roudi, Shahla Roudbar Mohammadi, Maryam Roudbary, et al.Investigational New Drugs|October 31, 2018
Lurbinectedin (PM01183), a selective inhibitor of active transcription, effectively eliminates both cancer cells and cancer stem cells in preclinical models of uterine cervical cancerEriko Yokoi, Seiji Mabuchi, Kotaro Shimura, et al.Pageof 372